Home › Endometrial Cancer › Delaware › Newark
Endometrial Cancer clinical trials in Newark, DE
4 studies for Endometrial Cancer are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Medical Oncology Hematology Consultants, Newark
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Newark
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Newark
- Non-Small Cell Lung Cancer15 studies
- Prostate Cancer10 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Metastatic Cancer8 studies
- Breast Cancer8 studies
- Pancreatic Cancer6 studies
- Cancer (all types)6 studies
- Ovarian Cancer5 studies
- Bladder Cancer4 studies
- Chronic Lymphocytic Leukemia4 studies
- Stomach Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.